查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1140204

核酸療法市場：按產品分類（反義寡核甘酸和 DNA 適體、RNA 干擾和短干擾 RNA 等）、按應用分類、按最終用戶分類：2021-2031 年全球機會分析和行業預測

Nucleic Acid Therapeutics Market By Products (Anti-Sense Oligonucleotides and DNA Aptamers, RNA Interference and Short Interfering RNAs, Others), By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 | 商品交期: 2-3個工作天內

價格

核酸是攜帶細胞遺傳信息的化學物質。

核酸分為三種類型：脫氧核糖核酸 (DNA)、核糖核酸 (RNA) 和人工核酸。 Watson-Crick 鹼基配對以序列特異性方式識別內源性核酸，並介導所有核酸共有的作用機制。基於核酸的療法被廣泛用於治療多種慢性疾病。核酸在癌症、腫瘤、糖尿病、肺結核和人類免疫缺陷病毒 (HIV) 等慢性疾病中顯示出巨大的治療益處。例如，近年來，世界核酸治療受到了極大的關注。此外，慢性病的增加和慢性病治療方法的探索是國際關注的問題，核酸治療越來越受到關注。

核酸療法通過基因編輯、基因抑制、基因添加和基因替換發揮長期作用。此外，慢性病患病率的增加和尋求核酸治療的患者數量的增加正在幫助全球核酸治療市場的增長。核酸療法顯示出長期的治愈效果。推動全球核酸治療市場增長的主要因素是慢性病患病率的增加和新型核酸治療藥物的不斷發展。高昂的研發成本和昂貴的治療和技術是製約市場增長的一些主要因素。核酸治療藥物開發的高產品需求和製藥公司日益集中是推動核酸治療市場增長的額外因素。癌症、肌營養不良症和人類免疫缺陷病毒 (HIV) 缺乏治療選擇是全球核酸治療市場擴大的關鍵原因。核酸治療市場審查批准用反義寡核甘酸治療澱粉樣變性以降低轉甲狀腺素蛋白 (TTR) 水平和 ISTH0036 在青光眼患者接受小梁切除術的安全性將通過劑量擴大進行改進例如，有多種療法正在籌備中，有望滿足全球對核酸療法的需求，並有助於市場的增長。

核酸療法根據產品、應用、最終用戶和地理位置進行細分。根據產品，市場分為反義寡核甘酸（ASOS）和DNA適體、RNA干擾[RNAi]和短干擾RNA[siRNA]等。還有一些被歸類為拮抗劑、RNA海綿和鎖定核酸。通過應用，市場分為單基因和多基因疾病。最終用戶分為醫院/診所和學術/研究機構。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概覽

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特五力分析
  • 主要公司的定位
  • 市場動態
    • 驅動程序
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章核酸療法市場：按產品分類

  • 概覽
    • 市場規模和預測
  • 反義寡核甘酸 (ASO) 和 DNA 適體
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • RNA 干擾 [RNAi]、短干擾 RNA [siRNA]
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章核酸療法市場：按應用分類

  • 概覽
    • 市場規模和預測
  • 單一疾病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 多基因疾病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章核酸療法市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院和診所
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 學術和研究機構
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章核酸療法市場：按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按產品分類
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按產品分類
    • 歐洲市場規模和預測：按應用
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按產品分類
    • 亞太市場規模和預測：按應用
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • LAMEA
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按產品分類
    • LAMEA 市場規模和預測：按應用
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章企業情況

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 競賽儀表板
  • 比賽熱圖
  • 主要發展

第 9 章公司簡介

  • Agilent Technologies
  • Alnylam Pharmaceuticals
  • Arbutus Biopharma
  • Arrrowhead
  • Benitec Biopharma
  • Caperna
  • Copernicus
  • Genzyme Sanofi
  • Ionis Pharmaceuticals
  • Merck
  • Novartis A.G
  • PYC Therapeutics Limited
  • Protagonist Therapeutics
  • Qaigen NV
  • Sarpeta Therapeutics
  • Silence Therapeutics
  • Thermo Fisher Scientific
  • Wavelifesciences
Product Code: A17089

Nucleic acids are chemical substances and carry genetic information of the cell. The three types of nucleic acids are deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and artificial nucleic acid. Watson-Crick base pairing recognizes endogenous nucleic acids in a sequence-specific manner, mediating the shared mode of action of all nucleic acids. The nucleic acid-based therapies are widely used to treat various chronic diseases. Nucleic acid shows the significant therapeutic result in chronic diseases, such as cancer, tumor, diabetes, tuberculosis, and human immunodeficiency virus (HIV). For instance, in recent years, the global nucleic acid therapeutics has gained extensive attention. Moreover, the increasing chronic illnesses and the search for cure of chronic illnesses is an international concern, therefore nucleic acid therapeutics is observing increased attention.

The nucleic acid therapeutics shows long lasting effects through gene editing, gene inhibition, gene addition or gene replacement. Furthermore, the increase in chronic disease prevalence and patients seeking treatment of nucleic acid therapies help in the global nucleic acid therapeutics market growth. Nucleic acid therapeutics shows the long lasting and curative effects. The key drivers for the growth of the global nucleic acid therapeutics market are increasing chronic illness and immensely developing novel treatments of nucleic acids. The high cost of research and development and expensive treatments and technologies are some major elements restraining the market growth. High product demand and growing concentration of pharmaceutical companies on the development of treatment for nucleic acid therapeutics are additional factors that are driving the nucleic acid therapeutics market growth. The lack of treatment alternatives for cancer, muscular dystrophy, and human immunodeficiency virus (HIV) is the important reason for global nucleic acid therapeutics market expansion. The nucleic acid therapeutics market will revamp on approval of the developing therapies for amyloidosis by using antisense oligonucleotide to lower transthyretin (TTR) levels and dose escalation to investigate safety of ISTH0036 in glaucoma undergoing trabeculectomy patients. For instance, there are various therapies under pipeline, which are expected to serve the demand for  nucleic acid therapies globally and contribute to the market growth.

The nucleic acid therapeutics is segmented on the basis of products, application, end user, and region. Based on the products, the market is bifurcated into anti-sense oligonucleotides (ASOS) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. The others segment is further classified into antagomir and RNA sponge and locked nucleic acid. By application, the market is fragmented into monogenetic disorders and multi-genetic disorders. By end user, the market is segmented into hospitals & clinics and academic & research institutes.

Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid therapeutics market analysis from 2021 to 2031 to identify the prevailing nucleic acid therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the nucleic acid therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global nucleic acid therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Products

  • Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
  • RNA interference [RNAi] and short interfering RNAs [siRNAs]
  • Others

By Application 

  • Monogenetic disorders
  • Multi-genetic disorders

By End User

  • Hospitals and Clinics
  • Academic and Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Agilent Technologies
    • Alnylam Pharmaceuticals
    • Arbutus Biopharma
    • Arrrowhead
    • Benitec Biopharma
    • Caperna
    • Copernicus
    • Genzyme Sanofi
    • Ionis Pharmaceuticals
    • Merck
    • Novartis A.G
    • PYC Therapeutics Limited
    • Protagonist Therapeutics
    • Qaigen NV
    • Sarpeta Therapeutics
    • Silence Therapeutics
    • Thermo Fisher Scientific
    • Wavelifesciences

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 RNA interference [RNAi] and short interfering RNAs [siRNAs]
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION 

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Monogenetic disorders
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Multi-genetic disorders
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: NUCLEIC ACID THERAPEUTICS MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals and Clinics
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Academic and Research Institutes
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: NUCLEIC ACID THERAPEUTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Products
    • 7.2.3 North America Market size and forecast, by Application 
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Products
      • 7.2.5.1.2 Market size and forecast, by Application 
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Products
      • 7.2.5.2.2 Market size and forecast, by Application 
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Products
      • 7.2.5.3.2 Market size and forecast, by Application 
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Products
    • 7.3.3 Europe Market size and forecast, by Application 
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Products
      • 7.3.5.1.2 Market size and forecast, by Application 
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Products
      • 7.3.5.2.2 Market size and forecast, by Application 
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Products
      • 7.3.5.3.2 Market size and forecast, by Application 
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Products
      • 7.3.5.4.2 Market size and forecast, by Application 
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Products
      • 7.3.5.5.2 Market size and forecast, by Application 
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Products
      • 7.3.5.6.2 Market size and forecast, by Application 
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Products
    • 7.4.3 Asia-Pacific Market size and forecast, by Application 
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Products
      • 7.4.5.1.2 Market size and forecast, by Application 
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Products
      • 7.4.5.2.2 Market size and forecast, by Application 
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Products
      • 7.4.5.3.2 Market size and forecast, by Application 
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Products
      • 7.4.5.4.2 Market size and forecast, by Application 
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Products
      • 7.4.5.5.2 Market size and forecast, by Application 
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Products
      • 7.4.5.6.2 Market size and forecast, by Application 
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Products
    • 7.5.3 LAMEA Market size and forecast, by Application 
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Products
      • 7.5.5.1.2 Market size and forecast, by Application 
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Products
      • 7.5.5.2.2 Market size and forecast, by Application 
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Products
      • 7.5.5.3.2 Market size and forecast, by Application 
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Products
      • 7.5.5.4.2 Market size and forecast, by Application 
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Agilent Technologies
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Alnylam Pharmaceuticals
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Arbutus Biopharma
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Arrrowhead
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Benitec Biopharma
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Caperna
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Copernicus
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Genzyme Sanofi
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Ionis Pharmaceuticals
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Merck
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Novartis A.G
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 PYC Therapeutics Limited
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
  • 9.13 Protagonist Therapeutics
    • 9.13.1 Company overview
    • 9.13.2 Company snapshot
    • 9.13.3 Operating business segments
    • 9.13.4 Product portfolio
    • 9.13.5 Business performance
    • 9.13.6 Key strategic moves and developments
  • 9.14 Qaigen NV
    • 9.14.1 Company overview
    • 9.14.2 Company snapshot
    • 9.14.3 Operating business segments
    • 9.14.4 Product portfolio
    • 9.14.5 Business performance
    • 9.14.6 Key strategic moves and developments
  • 9.15 Sarpeta Therapeutics
    • 9.15.1 Company overview
    • 9.15.2 Company snapshot
    • 9.15.3 Operating business segments
    • 9.15.4 Product portfolio
    • 9.15.5 Business performance
    • 9.15.6 Key strategic moves and developments
  • 9.16 Silence Therapeutics
    • 9.16.1 Company overview
    • 9.16.2 Company snapshot
    • 9.16.3 Operating business segments
    • 9.16.4 Product portfolio
    • 9.16.5 Business performance
    • 9.16.6 Key strategic moves and developments
  • 9.17 Thermo Fisher Scientific
    • 9.17.1 Company overview
    • 9.17.2 Company snapshot
    • 9.17.3 Operating business segments
    • 9.17.4 Product portfolio
    • 9.17.5 Business performance
    • 9.17.6 Key strategic moves and developments
  • 9.18 Wavelifesciences
    • 9.18.1 Company overview
    • 9.18.2 Company snapshot
    • 9.18.3 Operating business segments
    • 9.18.4 Product portfolio
    • 9.18.5 Business performance
    • 9.18.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 2. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. NUCLEIC ACID THERAPEUTICS MARKET FOR ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS], BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. NUCLEIC ACID THERAPEUTICS MARKET FOR RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS], BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. NUCLEIC ACID THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 9. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR MONOGENETIC DISORDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. NUCLEIC ACID THERAPEUTICS MARKET FOR MONOGENETIC DISORDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR MULTI-GENETIC DISORDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. NUCLEIC ACID THERAPEUTICS MARKET FOR MULTI-GENETIC DISORDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 14. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NUCLEIC ACID THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. NUCLEIC ACID THERAPEUTICS MARKET SIZE, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. NUCLEIC ACID THERAPEUTICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. NUCLEIC ACID THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 21. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. NORTH AMERICA NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. U.S. NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 24. U.S. NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 25. U.S. NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 26. CANADA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 27. CANADA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 28. CANADA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 29. MEXICO NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 30. MEXICO NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 31. MEXICO NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 32. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 33. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 34. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 35. EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 36. GERMANY NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 37. GERMANY NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 38. GERMANY NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 39. FRANCE NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 40. FRANCE NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 41. FRANCE NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 42. UK NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 43. UK NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 44. UK NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 45. ITALY NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 46. ITALY NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 47. ITALY NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 48. SPAIN NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 49. SPAIN NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 50. SPAIN NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 51. REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 52. REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 53. REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 54. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 55. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 56. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 57. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 58. JAPAN NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 59. JAPAN NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 60. JAPAN NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 61. CHINA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 62. CHINA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 63. CHINA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 65. AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 66. AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 67. INDIA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 68. INDIA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 69. INDIA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 70. SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 71. SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 72. SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 76. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 77. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 78. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 79. LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 80. BRAZIL NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 81. BRAZIL NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 82. BRAZIL NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 84. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 85. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 86. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 87. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 88. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS, 2021-2031 ($MILLION)
  • TABLE 90. REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION , 2021-2031 ($MILLION)
  • TABLE 91. REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 92.AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 93.AGILENT TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 94.AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 95.AGILENT TECHNOLOGIES: NET SALES,
  • TABLE 96.AGILENT TECHNOLOGIES: KEY STRATERGIES
  • TABLE 97.ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 98.ALNYLAM PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 99.ALNYLAM PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 100.ALNYLAM PHARMACEUTICALS: NET SALES,
  • TABLE 101.ALNYLAM PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 102.ARBUTUS BIOPHARMA: COMPANY SNAPSHOT
  • TABLE 103.ARBUTUS BIOPHARMA: OPERATING SEGMENTS
  • TABLE 104.ARBUTUS BIOPHARMA: PRODUCT PORTFOLIO
  • TABLE 105.ARBUTUS BIOPHARMA: NET SALES,
  • TABLE 106.ARBUTUS BIOPHARMA: KEY STRATERGIES
  • TABLE 107.ARRROWHEAD: COMPANY SNAPSHOT
  • TABLE 108.ARRROWHEAD: OPERATING SEGMENTS
  • TABLE 109.ARRROWHEAD: PRODUCT PORTFOLIO
  • TABLE 110.ARRROWHEAD: NET SALES,
  • TABLE 111.ARRROWHEAD: KEY STRATERGIES
  • TABLE 112.BENITEC BIOPHARMA: COMPANY SNAPSHOT
  • TABLE 113.BENITEC BIOPHARMA: OPERATING SEGMENTS
  • TABLE 114.BENITEC BIOPHARMA: PRODUCT PORTFOLIO
  • TABLE 115.BENITEC BIOPHARMA: NET SALES,
  • TABLE 116.BENITEC BIOPHARMA: KEY STRATERGIES
  • TABLE 117.CAPERNA: COMPANY SNAPSHOT
  • TABLE 118.CAPERNA: OPERATING SEGMENTS
  • TABLE 119.CAPERNA: PRODUCT PORTFOLIO
  • TABLE 120.CAPERNA: NET SALES,
  • TABLE 121.CAPERNA: KEY STRATERGIES
  • TABLE 122.COPERNICUS: COMPANY SNAPSHOT
  • TABLE 123.COPERNICUS: OPERATING SEGMENTS
  • TABLE 124.COPERNICUS: PRODUCT PORTFOLIO
  • TABLE 125.COPERNICUS: NET SALES,
  • TABLE 126.COPERNICUS: KEY STRATERGIES
  • TABLE 127.GENZYME SANOFI: COMPANY SNAPSHOT
  • TABLE 128.GENZYME SANOFI: OPERATING SEGMENTS
  • TABLE 129.GENZYME SANOFI: PRODUCT PORTFOLIO
  • TABLE 130.GENZYME SANOFI: NET SALES,
  • TABLE 131.GENZYME SANOFI: KEY STRATERGIES
  • TABLE 132.IONIS PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 133.IONIS PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 134.IONIS PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 135.IONIS PHARMACEUTICALS: NET SALES,
  • TABLE 136.IONIS PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 137.MERCK: COMPANY SNAPSHOT
  • TABLE 138.MERCK: OPERATING SEGMENTS
  • TABLE 139.MERCK: PRODUCT PORTFOLIO
  • TABLE 140.MERCK: NET SALES,
  • TABLE 141.MERCK: KEY STRATERGIES
  • TABLE 142.NOVARTIS A.G: COMPANY SNAPSHOT
  • TABLE 143.NOVARTIS A.G: OPERATING SEGMENTS
  • TABLE 144.NOVARTIS A.G: PRODUCT PORTFOLIO
  • TABLE 145.NOVARTIS A.G: NET SALES,
  • TABLE 146.NOVARTIS A.G: KEY STRATERGIES
  • TABLE 147.PYC THERAPEUTICS LIMITED: COMPANY SNAPSHOT
  • TABLE 148.PYC THERAPEUTICS LIMITED: OPERATING SEGMENTS
  • TABLE 149.PYC THERAPEUTICS LIMITED: PRODUCT PORTFOLIO
  • TABLE 150.PYC THERAPEUTICS LIMITED: NET SALES,
  • TABLE 151.PYC THERAPEUTICS LIMITED: KEY STRATERGIES
  • TABLE 152.PROTAGONIST THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 153.PROTAGONIST THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 154.PROTAGONIST THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 155.PROTAGONIST THERAPEUTICS: NET SALES,
  • TABLE 156.PROTAGONIST THERAPEUTICS: KEY STRATERGIES
  • TABLE 157.QAIGEN NV: COMPANY SNAPSHOT
  • TABLE 158.QAIGEN NV: OPERATING SEGMENTS
  • TABLE 159.QAIGEN NV: PRODUCT PORTFOLIO
  • TABLE 160.QAIGEN NV: NET SALES,
  • TABLE 161.QAIGEN NV: KEY STRATERGIES
  • TABLE 162.SARPETA THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 163.SARPETA THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 164.SARPETA THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 165.SARPETA THERAPEUTICS: NET SALES,
  • TABLE 166.SARPETA THERAPEUTICS: KEY STRATERGIES
  • TABLE 167.SILENCE THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 168.SILENCE THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 169.SILENCE THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 170.SILENCE THERAPEUTICS: NET SALES,
  • TABLE 171.SILENCE THERAPEUTICS: KEY STRATERGIES
  • TABLE 172.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 173.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 174.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 175.THERMO FISHER SCIENTIFIC: NET SALES,
  • TABLE 176.THERMO FISHER SCIENTIFIC: KEY STRATERGIES
  • TABLE 177.WAVELIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 178.WAVELIFESCIENCES: OPERATING SEGMENTS
  • TABLE 179.WAVELIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 180.WAVELIFESCIENCES: NET SALES,
  • TABLE 181.WAVELIFESCIENCES: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.NUCLEIC ACID THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.NUCLEIC ACID THERAPEUTICS MARKET,2021-2031
  • FIGURE 3.NUCLEIC ACID THERAPEUTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.NUCLEIC ACID THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.NUCLEIC ACID THERAPEUTICS MARKET,BY PRODUCTS,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS] NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 16.NUCLEIC ACID THERAPEUTICS MARKET,BY APPLICATION ,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MONOGENETIC DISORDERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MULTI-GENETIC DISORDERS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 19.NUCLEIC ACID THERAPEUTICS MARKET,BY END USER,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ACADEMIC AND RESEARCH INSTITUTES NUCLEIC ACID THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 22.NUCLEIC ACID THERAPEUTICS MARKET BY REGION,2021
  • FIGURE 23.U.S. NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 24.CANADA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 25.MEXICO NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 26.GERMANY NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 27.FRANCE NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.UK NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.ITALY NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.SPAIN NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF EUROPE NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.CHINA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.AUSTRALIA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.INDIA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.SOUTH KOREA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.BRAZIL NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.SAUDI ARABIA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH AFRICA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF LAMEA NUCLEIC ACID THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46.COMPETITIVE DASHBOARD
  • FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 48.AGILENT TECHNOLOGIES.: NET SALES ,($MILLION)
  • FIGURE 49.ALNYLAM PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 50.ARBUTUS BIOPHARMA.: NET SALES ,($MILLION)
  • FIGURE 51.ARRROWHEAD.: NET SALES ,($MILLION)
  • FIGURE 52.BENITEC BIOPHARMA.: NET SALES ,($MILLION)
  • FIGURE 53.CAPERNA.: NET SALES ,($MILLION)
  • FIGURE 54.COPERNICUS.: NET SALES ,($MILLION)
  • FIGURE 55.GENZYME SANOFI.: NET SALES ,($MILLION)
  • FIGURE 56.IONIS PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 57.MERCK.: NET SALES ,($MILLION)
  • FIGURE 58.NOVARTIS A.G.: NET SALES ,($MILLION)
  • FIGURE 59.PYC THERAPEUTICS LIMITED.: NET SALES ,($MILLION)
  • FIGURE 60.PROTAGONIST THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 61.QAIGEN NV.: NET SALES ,($MILLION)
  • FIGURE 62.SARPETA THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 63.SILENCE THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 64.THERMO FISHER SCIENTIFIC.: NET SALES ,($MILLION)
  • FIGURE 65.WAVELIFESCIENCES.: NET SALES ,($MILLION)